The Yakes AVM Classification System: Cracking the Code for Curative AVM Endovascular Treatment

Yakes, Alexis M.; Continenza, Alexander J.; Yakes, Wayne F.

doi:10.1007/978-981-15-9762-6_21

Cited by 4 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MST1, the ligand of RON, is two disulphide-linked peptide chains generated by proteolysis of a single gene product. Inhibitors capmatinib (pIC 50 9.9) [142], SGX-523 (pK d 9.7) [44], cabozantinib (pIC 50 8.9) [251] BMS-777607 (pIC 50 8.7) [201] Selective inhibitors SGX-523 (pIC 50 8.4) [25] -Comments: PF04217903 is a selective Met tyrosine kinase inhibitor [40]. SU11274 is an inhibitor of the HGF receptor [198], with the possibility of further targets [6].…”

Section: Type VIII Rtks: Ror Familymentioning

confidence: 99%

“…Searchable database: http://www.guidetopharmacology.org/index.jsp Type III RTKs: PDGFR, CSFR, Kit, FLT3 50 8.7)[185], CEP-11981 (pIC 50 8.5)[100], semaxanib (pIC 50 8.1)[17] cabozantinib (pIC 50 10.5)[251], axitinib (pIC 50 9.6)[130], foretinib (pIC 50 8.2-9.1)[170], cediranib (pK d 9)[44], tesevatinib (pIC 50 8.8)[70], motesanib (pK d 8.6)[44], famitinib (pIC 50 8.3)[32], axitinib (pK d 8.2)[44] …”

mentioning

confidence: 99%

See 1 more Smart Citation

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors

Alexander

Fabbro

Kelly

et al. 2021

British J Pharmacology

166

143

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.15541. Catalytic receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, ion channels, nuclear hormone receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

show abstract

Section: Type VIII Rtks: Ror Familymentioning

confidence: 99%

mentioning

confidence: 99%

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors

Alexander

Fabbro

Kelly

et al. 2021

British J Pharmacology

166

143

View full text Add to dashboard Cite

show abstract

“…VEGFB (VEGFB, P49765) and placental growth factor (PGF, P49763) activate VEGFR1 homodimers, while VEGFC (VEGFC, P49767) and VEGFD (VEGFD, O43915) activate VEGFR2/3 heterodimers and VEGFR3 homodimers, and, following proteolysis, VEGFR2 homodimers. cabozantinib (pIC 50 10.5) [239], axitinib (pIC 50 9.6) [123], foretinib (pIC 50 8.2-9.1) [162], cediranib (pK d 9) [42], tesevatinib (pIC 50 8.8) [67], motesanib (pK d 8.6) [42], famitinib (pIC 50 8.3) [30], axitinib (pK d 8.…”

Section: Overviewmentioning

confidence: 99%

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors

Alexander

Fabbro

Kelly

et al. 2019

British J Pharmacology

199

208

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (http://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.14751. Catalytic receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, ion channels, nuclear hormone receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

show abstract

“…Yakes classified PAVMs into six types (Ia, IIa, IIb, IIIa, IIIb and IV) based on nidus angioarchitecture, which is limited to ethanol use as the sole embolizing agent or in conjunction with mechanical occlusion (coils, or plugs), depending on the nidus type. 8 Risks associated with embolization, including surrounding tissue ischemia, nontarget embolization, intra or postprocedural vascular rupture and incomplete embolization of the AVM, warrant assessment of individualized benefit risk ratio and case-based treatment strategy. The sudden hemodynamic changes encountered following complete AVM embolization in one sitting is the likely explanation of post embolization rupture and bleed.…”

Section: Treatment Of High-flow Vascular Malformations (Hfvm)mentioning

confidence: 99%

“…Cho–Do et al 7 and Yakes 8 recently introduced classification systems for AVM, based on morphology of AVM and is helpful in guiding optimal mode of treatment.…”

Section: Introductionmentioning

confidence: 99%

Peripheral Arteriovenous Malformations: Imaging and Endovascular Management Strategies

Malik

Kramadhari

Rathod

et al. 2021

Journal of Clinical Interventional Radiology ISVIR

View full text Add to dashboard Cite

The peripheral high-flow vascular malformation (HFVM) comprises arteriovenous malformation (AVM) and fistula (AVF), shows varied clinical presentation (ranging from subtle skin lesion to life-threatening congestive heart failure), and frequently poses diagnostic and therapeutic challenges. Importance of assigning a specific diagnosis to the vascular malformation cannot be overstated, as the treatment strategy is based on the type of vascular anomaly. Although the International Society for the Study of Vascular Anomalies (ISSVA) classification system is the most commonly accepted system for classifying congenital vascular anomalies in clinical practice, the Cho–Do et al classification is of utmost help in guiding optimal mode of treatment in peripheral AVM. Although transarterial approach remains the most commonly employed route for peripheral AVM embolization, the role of transvenous and direct percutaneous approach is ever increasing and the final decision on the approach depends on angioarchitecture of the AVM. In this article, we review various commonly employed classification systems for congenital vascular anomalies, and describe clinical features, imaging and treatment strategies for peripheral arteriovenous malformation (PAVM).

show abstract

The Yakes AVM Classification System: Cracking the Code for Curative AVM Endovascular Treatment

Cited by 4 publications

References 27 publications

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors

Peripheral Arteriovenous Malformations: Imaging and Endovascular Management Strategies

Contact Info

Product

Resources

About